In September 2025, the U.S. government issued a warning suggesting a possible connection between acetaminophen use during pregnancy and an increased risk of autism and other neurodevelopmental disorders. For expectant parents who had relied on the over-the-counter pain and fever medication as one of the few options considered safe during pregnancy, the announcement was alarming.
A new meta-analysis is now offering a more measured picture. The review, which examined high-quality studies conducted across multiple countries, found no evidence supporting a causal link between prenatal acetaminophen exposure and autism spectrum disorder, ADHD or intellectual disabilities. When taken as directed, the research concludes, acetaminophen does not appear to raise the risk of neurodevelopmental conditions in children.
What made this analysis different from earlier research
Earlier studies that raised concerns about acetaminophen and autism were criticized for methodological limitations, particularly their inability to account for genetic predispositions and environmental variables that independently affect neurodevelopmental outcomes. A child whose mother took acetaminophen for a high fever during pregnancy may have had elevated risk factors entirely unrelated to the medication itself.
The new meta-analysis addressed that weakness directly by prioritizing sibling comparison studies, a research design that controls for shared genetic and environmental factors by comparing outcomes between siblings with different levels of prenatal exposure. That approach significantly narrows the variables in play and produces a more reliable signal.
Researchers found no significant association between acetaminophen use during pregnancy and the development of autism spectrum disorder or intellectual disabilities across the studies reviewed. The findings align with large national registry studies that have tracked outcomes over longer periods.
Why untreated fever carries its own risks
Experts involved in discussing the findings have been careful to frame the reassurance within a broader clinical context. Avoiding acetaminophen during pregnancy out of fear is not a risk-free choice. Untreated fevers carry documented risks of their own, including miscarriage and congenital complications, particularly in the first trimester when fetal development is most vulnerable.
That means the relevant question for most pregnant people is not whether to take acetaminophen in isolation but how to weigh the risks of a fever going untreated against the risks of the medication used to treat it. The new research shifts that calculation by removing what had been a speculative but anxiety-inducing variable from the equation.
Acetaminophen, sold in the United States primarily under the brand name Tylenol, is among the most widely used medications during pregnancy globally. Fear-driven avoidance, without clinical guidance, can lead to outcomes worse than those it is trying to prevent.
The genetics of autism and what research still does not know
One thread running through the expert commentary on this analysis is a broader point about how autism and ADHD develop. Both are understood to be multifactorial conditions with significant genetic components. No single environmental exposure has been identified as a cause, and attributing either condition to a specific medication taken during pregnancy oversimplifies what researchers still do not fully understand about their origins.
That complexity does not mean environmental factors are irrelevant. It means that isolating any one factor, including a common medication, as a driver of neurodevelopmental outcomes requires a level of methodological rigor that earlier acetaminophen studies did not consistently meet. The new meta-analysis applied that rigor and found the feared connection does not hold up.
What this means for expectant parents
The research does not suggest acetaminophen should be taken casually or without reason during pregnancy. The recommendation remains to use the lowest effective dose for the shortest necessary duration, in consultation with a healthcare provider.
What the findings do offer is a more solid evidentiary basis for that conversation. The 2025 federal warning generated significant anxiety without the kind of methodological support that the new analysis now provides in the opposite direction. Pregnant people managing pain or fever can approach that decision with less fear that they are trading one risk for another.
